Urologix Company Profile (OTCMKTS:ULGX)

About Urologix (OTCMKTS:ULGX)

Urologix logo21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:ULGX
  • CUSIP: N/A
  • Web: www.urologix.com
Average Prices:
  • 52 Week Range: $0.00 - $0.00
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: -0.01
  • P/E Growth:
Sales & Book Value:
  • Annual Revenue: $12 million
  • Price / Sales: 0.00
  • Book Value: ($0.38) per share
  • Price / Book: 0.00
  • EBIDTA: ($372,999.00)
  • Average Volume: 36,586 shs.
  • Beta: 5.4
  • Short Ratio: 1.02

Frequently Asked Questions for Urologix (OTCMKTS:ULGX)

What is Urologix's stock symbol?

Urologix trades on the OTCMKTS under the ticker symbol "ULGX."

How were Urologix's earnings last quarter?

Urologix Inc. (OTCMKTS:ULGX) posted its quarterly earnings results on Thursday, February, 5th. The company reported ($0.02) EPS for the quarter. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.80 million. View Urologix's Earnings History.

Who are some of Urologix's key competitors?

Who are Urologix's key executives?

Urologix's management team includes the folowing people:

  • Gregory J. Fluet, Chief Executive Officer, Director
  • Scott M Madson, Chief Financial Officer
  • Lisa A. Ackermann, Executive Vice President - Sales and Marketing
  • Mitchell Dann, Independent Non-Executive Chairman of the Board, Lead Director
  • Christopher R. Barys, Independent Director
  • Sidney W. Emery Jr., Independent Director
  • Patrick D. Spangler, Independent Director

How do I buy Urologix stock?

Shares of Urologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urologix's stock price today?

One share of Urologix stock can currently be purchased for approximately $0.00.

MarketBeat Community Rating for Urologix (OTCMKTS ULGX)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  23
MarketBeat's community ratings are surveys of what our community members think about Urologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Urologix (OTCMKTS:ULGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Urologix (OTCMKTS:ULGX)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Urologix (OTCMKTS:ULGX)
Earnings by Quarter for Urologix (OTCMKTS:ULGX)
Earnings History by Quarter for Urologix (OTCMKTS ULGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2015Q215($0.02)$3.80 million$3.10 millionViewListenView Earnings Details
8/19/2014Q4 14($0.17)$3.29 millionViewN/AView Earnings Details
2/4/2014Q4($0.05)$3.81 millionViewListenView Earnings Details
11/14/2012Q113($0.06)($0.05)$4.48 million$4.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Urologix (OTCMKTS:ULGX)
Current Year EPS Consensus Estimate: $-0.21000 EPS
Next Year EPS Consensus Estimate: $-0.23000 EPS


Dividend History for Urologix (OTCMKTS:ULGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Urologix (OTCMKTS:ULGX)
Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 0.28%
Insider Trades by Quarter for Urologix (OTCMKTS:ULGX)
Insider Trades by Quarter for Urologix (OTCMKTS:ULGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/26/2013Gregory FluetCEOBuy17,500$0.31$5,425.00View SEC Filing  
7/12/2013Mitchell DannDirectorBuy20,000$0.30$6,000.00View SEC Filing  
7/10/2013Gregory FluetCEOBuy25,000$0.24$6,000.00View SEC Filing  
7/9/2013Lisa A AckermannEVPBuy18,500$0.24$4,440.00View SEC Filing  
7/8/2013Gregory FluetCEOBuy66,400$0.19$12,616.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Urologix (OTCMKTS:ULGX)
Latest Headlines for Urologix (OTCMKTS:ULGX)



Urologix (ULGX) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff